Title : Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.

Pub. Date : 2010 Jun

PMID : 19636701






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Tamoxifen cyclin D1 Homo sapiens
2 Both CCND1 and EMSY amplifications were associated with a significantly worse outcome in ER-positive patients treated with tamoxifen only, in contrast to nonamplified tumors (P = 8.55 x 10(-4) and P = 8.35 x 10(-5), respectively). Tamoxifen cyclin D1 Homo sapiens
3 In summary, co-amplification of CCND1 and EMSY identified a poor prognostic subset of ER-positive tamoxifen-treated patients. Tamoxifen cyclin D1 Homo sapiens